BCAL Diagnostics is a listed breast cancer biotech. The company has closed an oversubscribed fundraising round totalling $10.5 million. The raise was supported by existing backers including Ellerston Capital, APS Foundation and tech entrepreneur Mark McConnell. BCAL initially sought $5 million but was able to raise roughly twice that amount. The company will seek shareholder approval on July 15 for proceeds that fell outside its annual placement capacity. The article does not disclose operating metrics, product details, or use of proceeds.

Total raised

$11M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024